BACKGROUND: The use of corticosteroids for treating tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM) has yielded controversial results. We report the use of corticosteroids for the treatment of TSP/HAM in an open cohort. METHODS: The clinical efficacy of long-term, high dose of corticosteroid therapy was studied in thirty-nine TSP/HAM patients. Disability and motor dysfunction was evaluated based on the Disability Status Scale (DSS), Osame's Motor Disability Scales (OMDS), and Incapacity Status Scale (ISS), before and after treatment. Treatment included use of methyl-prednisolone, 1 g/day for three days, every 3-4 months. The primary end-point was a change in the scores of the neurological scales from baseline until the fifth visit after therapy. RESULTS: After a mean follow-up of 2.2 years and an average of four pulses per patient, we noted a significant neurological improvement, reaching 24.5% according to the ISS score. No statistically significant differences in scores according to the OMDS and DSS scales were noted. CONCLUSION: We observed neurological improvement with the use of corticosteroids, with physical therapy and antispastic-drugs as adjunctive treatment. However, randomized clinical trials should be done to assess the use of corticosteroids and other potentially useful immune-based therapies for TSP/HAM treatment.
BACKGROUND: The use of corticosteroids for treating tropical spastic paraparesis/HTLV-1 associated myelopathy (TSP/HAM) has yielded controversial results. We report the use of corticosteroids for the treatment of TSP/HAM in an open cohort. METHODS: The clinical efficacy of long-term, high dose of corticosteroid therapy was studied in thirty-nine TSP/HAM patients. Disability and motor dysfunction was evaluated based on the Disability Status Scale (DSS), Osame's Motor Disability Scales (OMDS), and Incapacity Status Scale (ISS), before and after treatment. Treatment included use of methyl-prednisolone, 1 g/day for three days, every 3-4 months. The primary end-point was a change in the scores of the neurological scales from baseline until the fifth visit after therapy. RESULTS: After a mean follow-up of 2.2 years and an average of four pulses per patient, we noted a significant neurological improvement, reaching 24.5% according to the ISS score. No statistically significant differences in scores according to the OMDS and DSS scales were noted. CONCLUSION: We observed neurological improvement with the use of corticosteroids, with physical therapy and antispastic-drugs as adjunctive treatment. However, randomized clinical trials should be done to assess the use of corticosteroids and other potentially useful immune-based therapies for TSP/HAM treatment.
Authors: A Cucca; L Stragapede; L Antonutti; M Catalan; I Caracciolo; Romina Valentinotti; A Granato; P D'Agaro; P Manganotti Journal: J Neurovirol Date: 2016-05-31 Impact factor: 2.643
Authors: Gabriela Prates; Tatiane Assone; Marcelo Corral; Maíra P M Baldassin; Tatiane Mitiko; Flávia C Silva Sales; Michel E Haziot; Jerusa Smid; Luiz A M Fonseca; Fernanda de Toledo Gonçalves; Augusto C Penalva de Oliveira; Jorge Casseb Journal: Neurol Clin Pract Date: 2021-04
Authors: Fabiola Martin; Hannah Castro; Carolyn Gabriel; Adine Adonis; Alexandra Fedina; Linda Harrison; Liz Brodnicki; Maria A Demontis; Abdel G Babiker; Jonathan N Weber; Charles R M Bangham; Graham P Taylor Journal: PLoS Negl Trop Dis Date: 2012-06-12
Authors: R M Castilhos; D Blank; C B O Netto; C F M Souza; L N T Fernandes; I V D Schwartz; R Giugliani; L B Jardim Journal: Braz J Med Biol Res Date: 2012-05-10 Impact factor: 2.590